Expanding innovative portfolio may drive gains for Sun Pharma stock
Lerodalcibep licensing deal, growth in the US portfolio and tariff relief offer triggers, while the proposed Organon acquisition could broaden its global reach
We haven't written up this one. Business Standard IN has the full story — the link below goes straight to it.